Ken Griffin Citadel Advisors
Ken Griffin founded Citadel, one of the world’s largest and most successful hedge funds. Starting his trading career from his Harvard dorm room at a young age, Griffin quickly developed a keen sense for markets and built Citadel into a global powerhouse with billions in assets under management. Known for his quantitative and technology-driven strategies, Griffin has also made headlines for significant philanthropic contributions, supporting causes in education, the arts, and public institutions. Over the years, he has earned recognition as one of the preeminent figures in modern finance.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$772M |
| 2 |
Eli Lilly
LLY
|
+$337M |
| 3 |
lululemon athletica
LULU
|
+$301M |
| 4 |
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
|
+$297M |
| 5 |
ResMed
RMD
|
+$273M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$576M |
| 2 |
AT&T
T
|
+$476M |
| 3 |
PNC Financial Services
PNC
|
+$393M |
| 4 |
Fortive
FTV
|
+$389M |
| 5 |
Accenture
ACN
|
+$374M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 2.83% |
| 2 | Technology | 2.79% |
| 3 | Financials | 2.29% |
| 4 | Consumer Discretionary | 1.93% |
| 5 | Industrials | 1.63% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
TE
4751
CALL
T1 Energy
TE
$1.51B
| $2.86M | ﹤0.01% |
417,700
+218,700
| +110% | +$1.92M |
|
4752
CALL
Boise Cascade
BCC
$2.9B
| $2.86M | ﹤0.01% |
48,000
-4,800
| -9% | -$354K |
|
4753
Cytek Biosciences
CTKB
$610M
| $2.84M | ﹤0.01% |
264,928
+239,579
| +945% | +$2.38M |
|
4754
CALL
iRhythm Holdings
IRTC
$4.17B
| $2.84M | ﹤0.01% |
26,300
-4,300
| -14% | -$570K |
|
|
BENE
4755
CALL
DELISTED
Benessere Capital Acquisition Corp. Class A Common Stock
BENE
| $2.84M | ﹤0.01% |
275,000
+20,600
| +8% | +$212K |
|
4756
CALL
iShares 1-3 Year Treasury Bond ETF
SHY
$25.5B
| $2.84M | ﹤0.01% |
34,300
-61,900
| -64% | -$5.14M |
|
4757
GoodRx Holdings
GDRX
$1.27B
| $2.84M | ﹤0.01% |
479,442
+423,994
| +765% | +$4.72M |
|
4758
PUT
10x Genomics
TXG
$7.31B
| $2.84M | ﹤0.01% |
62,700
+36,900
| +143% | +$1.91M |
|
4759
The Joint Corp
JYNT
$120M
| $2.84M | ﹤0.01% |
185,258
+143,968
| +349% | +$3.22M |
|
4760
PUT
PACCAR
PCAR
$68.8B
| $2.83M | ﹤0.01% |
51,600
+19,500
| +61% | +$1.1M |
|
|
JAMF
4761
DELISTED
Jamf
JAMF
| $2.83M | ﹤0.01% |
114,336
+39,675
| +53% | +$1.11M |
|
4762
CALL
Silicon Laboratories
SLAB
$7.29B
| $2.83M | ﹤0.01% |
20,200
-13,900
| -41% | -$1.95M |
|
4763
Abercrombie & Fitch
ANF
$4.8B
| $2.83M | ﹤0.01% |
167,322
+75,987
| +83% | +$2.1M |
|
4764
Schwab 1-5 Year Corporate Bond ETF
SCHJ
$849M
| $2.83M | ﹤0.01% |
119,224
-131,700
| -52% | -$3.15M |
|
4765
Veeco
VECO
$3.2B
| $2.83M | ﹤0.01% |
145,734
-75,469
| -34% | -$1.67M |
|
4766
CALL
Jack Henry & Associates
JKHY
$10.9B
| $2.83M | ﹤0.01% |
15,700
+3,800
| +32% | +$712K |
|
|
CORZ
4767
DELISTED
Core Scientific, Inc. Common Stock
CORZ
| $2.83M | ﹤0.01% |
+1,896,856
| New | +$8.72M |
|
4768
Janus Henderson B-BBB CLO ETF
JBBB
$1.43B
| $2.82M | ﹤0.01% |
+61,877
| New | +$2.96M |
|
4769
CALL
Willis Towers Watson
WTW
$30.8B
| $2.82M | ﹤0.01% |
14,300
-11,600
| -45% | -$2.49M |
|
4770
Sempra
SRE
$56.5B
| $2.82M | ﹤0.01% |
37,546
+12,392
| +49% | +$995K |
|
4771
Intrepid Potash
IPI
$493M
| $2.82M | ﹤0.01% |
62,240
+37,206
| +149% | +$2.71M |
|
4772
CALL
iShares MSCI South Africa ETF
EZA
$560M
| $2.82M | ﹤0.01% |
66,300
+57,900
| +689% | +$2.74M |
|
4773
CALL
Gossamer Bio
GOSS
$75.4M
| $2.82M | ﹤0.01% |
336,400
-158,700
| -32% | -$1.23M |
|
4774
CALL
Invesco
IVZ
$14.4B
| $2.82M | ﹤0.01% |
174,600
-126,300
| -42% | -$2.39M |
|
4775
Clover Health Investments
CLOV
$2.44B
| $2.81M | ﹤0.01% |
1,315,100
-627,379
| -32% | -$1.67M |
|
Similar funds
Ken Griffin's Q2 2022 Portfolio in Review
As of Q2 2022, Ken Griffin held 14,957 positions worth $390B, down 20% from $484B the previous quarter. Its ten largest holdings account for 28% of the portfolio.
Ken Griffin's Q2 2022 filing shows 1,520 new, 5,503 increased, 5,522 reduced and 2,191 closed positions. Its largest new stake was ResMed: 1,280,595 shares worth $268M. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $576M.
By sector, the portfolio is most concentrated in Healthcare at 2.8% of assets, up from 2.4% a quarter earlier, followed by Technology and Financials.
- Ken Griffin's largest Q2 2022 buy was ResMed: 1,280,595 shares worth $268M.
- Ken Griffin added most to Meta Platforms (Facebook) in Q2 2022, an estimated $772M increase.
- Ken Griffin's biggest Q2 2022 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $576M.
- Ken Griffin fully exited Vanguard Morningstar Small-Cap ETF in Q2 2022, selling an estimated $184M.
- Ken Griffin's ten largest holdings make up 28% of its $390B portfolio in Q2 2022.
- Ken Griffin opened 1,520 new positions and closed 2,191 in Q2 2022.
- Ken Griffin's portfolio value fell 20% quarter-over-quarter to $390B.
Based on Citadel Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.